Primary antiphospholipid syndrome evolving into systemic lupus erythematosus

被引:1
作者
Derksen, RHWM
GmeligMeijling, FHJ
deGroot, PG
机构
[1] UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS
[2] UNIV UTRECHT HOSP,DEPT HAEMATOL,3508 GA UTRECHT,NETHERLANDS
关键词
anticardiolipin antibodies; lupus anticoagulant; antiphospholipid syndrome; systemic lupus erythematosus;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A young woman had a history of spontaneous venous thromboembolic disease which recurred on several occasions after cessation of treatment with oral anticoagulants. The presence of antiphospholipid antibodies (lupus anticoagulant and a high titre of IgG class anticardiolipin antibodies) in the absence of other clinical and serological features of systemic lupus erythematosus (SLE) confirmed a diagnosis of primary 'antiphospholipid syndrome (PAPS). Antinuclear antibodies (ANA) were positive (1:1280; speckled pattern). Twelve years after the first thrombotic episode she fulfilled criteria for the classification of SLE (antinuclear antibodies, platelet count < 100 x 10(9)/1, anti-dsDNA antibodies, Coombs' positive haemolytic anaemia). She suffered a myocardial infarction while adequately anticoagulated and developed polyarthritis and immune complex-mediated nephritis over the next 3 years. This case history supports suggestions made by others that a strongly positive ANA test in a patient diagnosed with PAPS may be a harbinger for the development of SLE. Such evolution can take place over more than 10 years.
引用
收藏
页码:77 / 80
页数:4
相关论文
共 15 条
[1]  
ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482
[2]  
ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P1359
[3]   ANTIPHOSPHOLIPID SYNDROME AND SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
ANDREWS, PA ;
FRAMPTON, G ;
CAMERON, JS .
LANCET, 1993, 342 (8877) :988-989
[4]   THE PRIMARY ANTIPHOSPHOLIPID SYNDROME - MAJOR CLINICAL AND SEROLOGICAL FEATURES [J].
ASHERSON, RA ;
KHAMASHTA, MA ;
ORDIROS, J ;
DERKSEN, RHWM ;
MACHIN, SJ ;
BARQUINERO, J ;
OUTT, HH ;
HARRIS, EN ;
VILARDELLTORRES, M ;
HUGHES, GRV .
MEDICINE, 1989, 68 (06) :366-374
[5]  
ASHERSON RA, 1988, J RHEUMATOL, V15, P1742
[6]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[7]   PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES AND VENOUS THROMBOSIS SHOULD RECEIVE LONG-TERM ANTICOAGULANT TREATMENT [J].
DERKSEN, RHWM ;
DEGROOT, PG ;
KATER, L ;
NIEUWENHUIS, HK .
ANNALS OF THE RHEUMATIC DISEASES, 1993, 52 (09) :689-692
[8]   COAGULATION SCREEN IS MORE SPECIFIC THAN THE ANTICARDIOLIPIN ANTIBODY ELISA IN DEFINING A THROMBOTIC SUBSET OF LUPUS PATIENTS [J].
DERKSEN, RHWM ;
HASSELAAR, P ;
BLOKZIJL, L ;
MEYLING, FHJG ;
DEGROOT, PG .
ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (05) :364-371
[9]   MULTIPLE SUBUNGUAL SPLINTER HEMORRHAGES IN THE ANTIPHOSPHOLIPID SYNDROME - A REPORT OF 5 CASES AND REVIEW OF THE LITERATURE [J].
FRANCES, C ;
PIETTE, JC ;
SAADA, V ;
PAPO, T ;
WECHSLER, B ;
CHOSIDOW, O ;
GODEAU, P .
LUPUS, 1994, 3 (02) :123-128
[10]  
HARRIS E N, 1987, British Journal of Rheumatology, V26, P19